company background image
ZYXI

ZynexNasdaqGS:ZYXI Stock Report

Last Price

US$8.42

Market Cap

US$326.1m

7D

0%

1Y

-48.0%

Updated

19 Jan, 2022

Data

Company Financials +
ZYXI fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance1/6
Financial Health6/6
Dividends0/6

ZYXI Stock Overview

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.

Price History & Performance

Summary of all time highs, changes and price drops for Zynex
Historical stock prices
Current Share PriceUS$8.42
52 Week HighUS$20.81
52 Week LowUS$8.05
Beta0.77
1 Month Change-5.30%
3 Month Change-24.88%
1 Year Change-48.03%
3 Year Change169.24%
5 Year Change2,907.14%
Change since IPO294.13%

Recent News & Updates

Shareholder Returns

ZYXIUS Medical EquipmentUS Market
7D0%-4.8%-4.6%
1Y-48.0%-0.4%7.7%

Return vs Industry: ZYXI underperformed the US Medical Equipment industry which returned 0.8% over the past year.

Return vs Market: ZYXI underperformed the US Market which returned 10.2% over the past year.

Price Volatility

Is ZYXI's price volatile compared to industry and market?
ZYXI volatility
ZYXI Average Weekly Movement7.8%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: ZYXI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ZYXI's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996768Thomas Sandgaardhttps://www.zynex.com

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support.

Zynex Fundamentals Summary


Earnings & Revenue

Key profitability statistics from the latest earnings report
ZYXI income statement (TTM)
RevenueUS$115.54m
Cost of RevenueUS$24.91m
Gross ProfitUS$90.63m
ExpensesUS$80.64m
EarningsUS$10.00m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.26
Gross Margin78.44%
Net Profit Margin8.65%
Debt/Equity Ratio0%

How did ZYXI perform over the long term?

See historical performance and comparison

Valuation

Is Zynex undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ZYXI ($8.42) is trading below our estimate of fair value ($52.92)

Significantly Below Fair Value: ZYXI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ZYXI is good value based on its PE Ratio (32.6x) compared to the US Medical Equipment industry average (46.7x).

PE vs Market: ZYXI is poor value based on its PE Ratio (32.6x) compared to the US market (17x).


Price to Earnings Growth Ratio

PEG Ratio: ZYXI is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: ZYXI is overvalued based on its PB Ratio (5.1x) compared to the US Medical Equipment industry average (3.5x).


Future Growth

How is Zynex forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

52.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYXI's forecast earnings growth (52.8% per year) is above the savings rate (2%).

Earnings vs Market: ZYXI's earnings (52.8% per year) are forecast to grow faster than the US market (13% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ZYXI's revenue (32.2% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: ZYXI's revenue (32.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ZYXI's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Zynex performed over the past 5 years?

21.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ZYXI has a high level of non-cash earnings.

Growing Profit Margin: ZYXI's current net profit margins (8.7%) are lower than last year (14.9%).


Past Earnings Growth Analysis

Earnings Trend: ZYXI has become profitable over the past 5 years, growing earnings by 21% per year.

Accelerating Growth: ZYXI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ZYXI had negative earnings growth (-2.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (51.2%).


Return on Equity

High ROE: ZYXI's Return on Equity (15.8%) is considered low.


Financial Health

How is Zynex's financial position?


Financial Position Analysis

Short Term Liabilities: ZYXI's short term assets ($69.9M) exceed its short term liabilities ($10.3M).

Long Term Liabilities: ZYXI's short term assets ($69.9M) exceed its long term liabilities ($17.0M).


Debt to Equity History and Analysis

Debt Level: ZYXI is debt free.

Reducing Debt: ZYXI currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: ZYXI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ZYXI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Zynex current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZYXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZYXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZYXI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZYXI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZYXI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Thomas Sandgaard (62 yo)

26yrs

Tenure

US$905,453

Compensation

Mr. Thomas Sandgaard founded Zynex, Inc. in 1996 and has been its Chairman, Chief Executive Officer and President since 1996. Mr. Sandgaard served as the Chief Financial Officer and Chief Accounting Office...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD905.45K) is below average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: Thomas's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

Experienced Management: ZYXI's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: ZYXI's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Zynex, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Zynex, Inc.
  • Ticker: ZYXI
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$326.088m
  • Shares outstanding: 38.73m
  • Website: https://www.zynex.com

Number of Employees


Location

  • Zynex, Inc.
  • 9555 Maroon Circle
  • Englewood
  • Colorado
  • 80112
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 23:40
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.